B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

Oncology·MeSH: Burkitt Lymphoma

Prevalence

8.0 / 100K

Incidence

1.8 / 100K/yr

12 drugs in development·1 company·4 clinical trials

Drug Pipeline by Phase

Phase 3(11)

Drug	Company
Asparaginase Erwinia chrysanthemi	Assertio Holdings, Inc. (ASRT)
Cytarabine	Assertio Holdings, Inc. (ASRT)
Daunorubicin	Assertio Holdings, Inc. (ASRT)
Daunorubicin Hydrochloride	Assertio Holdings, Inc. (ASRT)
Dexrazoxane Hydrochloride	Assertio Holdings, Inc. (ASRT)
Liposome-encapsulated Daunorubicin-Cytarabine	Assertio Holdings, Inc. (ASRT)
Mercaptopurine	Assertio Holdings, Inc. (ASRT)
Mercaptopurine Oral Suspension	Assertio Holdings, Inc. (ASRT)
Mitoxantrone Hydrochloride	Assertio Holdings, Inc. (ASRT)
Ponatinib Hydrochloride	Assertio Holdings, Inc. (ASRT)
Vincristine Sulfate	Assertio Holdings, Inc. (ASRT)

Phase 2(1)

Drug	Company
6-Mercaptopurine	Assertio Holdings, Inc. (ASRT)

BioSniper tracks 12 drugs in development for B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative across 1 company.

There are 4 clinical trials targeting B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative tracked by BioSniper.

The estimated prevalence of B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative is approximately 8.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.